{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:21:22Z","timestamp":1761513682348,"version":"3.41.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"DOI":"10.2146\/ajhp140290","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T16:50:41Z","timestamp":1440089441000},"page":"1445-1455","source":"Crossref","is-referenced-by-count":16,"title":["Simeprevir and sofosbuvir for treatment of hepatitis C infection"],"prefix":"10.1093","volume":"72","author":[{"given":"Shelby","family":"Chopp","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital of Michigan, Detroit; at the time of writing she was Pharm.D. student, Ferris State University College of Pharmacy, Kalamazoo, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Vanderwall","sequence":"additional","affiliation":[{"name":"Indiana University Health, Indianapolis, IN; at the time of writing she was Pharm.D. student, Ferris State University College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Hult","sequence":"additional","affiliation":[{"name":"Bronson Methodist Hospital, Kalamazoo, MI; at the time of writing she was Pharm.D. student, Ferris State University College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Klepser","sequence":"additional","affiliation":[{"name":"Pharmacy Practice, Ferris State University College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041008411116300_b1-0721445","unstructured":"World Health Organization. Hepatitis C. www.who.int\/mediacentre\/factsheets\/fs164\/en\/ (accessed 2013 Nov 6)."},{"key":"key\n\t\t\t\t2019041008411116300_b2-0721445","unstructured":"Pollack A . Hepatitis C, a silent killer, meets its match (November04, 2013). www.nytimes.com\/2013\/11\/05\/health\/hepatitis-c-a-silent-killer-meets-its-match.html?pagewanted=1&_r=0 (accessed 2013 Nov 14)."},{"key":"key\n\t\t\t\t2019041008411116300_b3-0721445","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","article-title":"Sofosbuvir: a review of its use in patients with chronic hepatitis C","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041008411116300_b4-0721445","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019041008411116300_b5-0721445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2013.08.019","article-title":"Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents","volume":"68","author":"Conteduca","year":"2014","journal-title":"J Infect"},{"key":"key\n\t\t\t\t2019041008411116300_b6-0721445","unstructured":"Janssen Therapeutics. Highlights of prescribing information for Olysio (simeprevir). www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf (accessed 2015 Jun 3)."},{"key":"key\n\t\t\t\t2019041008411116300_b7-0721445","unstructured":"Janssen Therapeutics. Simeprevir (TMC435): NDA 205123 (October24, 2013). www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM371624.pdf (accessed 2015 May 26)."},{"key":"key\n\t\t\t\t2019041008411116300_b8-0721445","unstructured":"Gilead Sciences. Highlights of prescribing information for Sovaldi (sofosbuvir). www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/sovaldi\/sovaldi_pi.pdf (accessed 2015 Jun 15)."},{"key":"key\n\t\t\t\t2019041008411116300_b9-0721445","unstructured":"ClinicalTrials.gov. A study of TMC435 in combination with pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 hepatitis C virus who never received treatment (PILLAR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00882908 (accessed 2015 May 26)."},{"key":"key\n\t\t\t\t2019041008411116300_b10-0721445","unstructured":"ClinicalTrials.gov. A safety and effectiveness study of TMC435 in chronic, genotype 1, hepatitis C patients who failed to previous standard treatment (ASPIRE). https:\/\/clinicaltrials.gov\/show\/NCT00980330 (accessed 2015 May 26)."},{"key":"key\n\t\t\t\t2019041008411116300_b11-0721445","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041008411116300_b12-0721445","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041008411116300_b13-0721445","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019041008411116300_b14-0721445","unstructured":"American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org\/full-report (accessed 2015 Jun 1)."},{"key":"key\n\t\t\t\t2019041008411116300_b15-0721445","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008411116300_b16-0721445","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-na\u00efve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041008411116300_b17-0721445","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041008411116300_b18-0721445","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041008411116300_b19-0721445","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008411116300_b20-0721445","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008411116300_b21-0721445","unstructured":"Terhune C Brown E . Prices of new hepatitis C drugs are tough to swallow for insurers (March09, 2014). www.latimes.com\/business\/la-fi-hepatitis-c-drug-costs-20140310,0,5308461.story?page=2#axzz2vfZIwGi5 (accessed 2014 Mar 11)."},{"key":"key\n\t\t\t\t2019041008411116300_b22-0721445","unstructured":"Tucker M . Costs for hepatitis C treatment skyrocket (November13, 2013). www.medscape.com\/viewarticle\/814295 (accessed 2014 Mar 11)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/72\/17\/1445\/28320561\/ajhp1445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T03:09:12Z","timestamp":1748574552000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/72\/17\/1445\/5111432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,1]]},"references-count":22,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140290","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2015,9,1]]},"published":{"date-parts":[[2015,9,1]]}}}